32.49
32.49 (-0.13%)
As of Mar 09, 2021
Immunitybio, Inc. [NK]
Source:
Company Overview
ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The company’s range of immunotherapy platforms, alone and together, act to drive an immune response with the goal of creating durable immune memory generating safe protection against disease.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | ( 844 ) 696-5235 |
| Industry | manufacturing |
| CEO | Richard Adcock |
| Website | https://www.immunitybio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $14.7 |
| Operating Profit | $-344.2 |
| Net Income | $-413.6 |
| Net Cash | $-121.9 |
Profit Ratios
| Gross Margin | $14.7 |
| Operating Margin | -2,334.2 |
| Profit as % of Revenues | -3.6% |
| Profit as % of Assets | -93.2% |
| Profit as % of Stockholder Equity | 84.7% |
Management Effectiveness
| Return on Equity | 84.7% |
| Return on Assets | -108% |
| Turnover Ratio | 3.3% |
| EBITA | $-344.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $382.9 |
| Total Liabilities | $871.1 |
| Operating Cash Flow | $-391.2 |
| Investing Cash Flow | $-12.2 |
| Financing Cash Flow | $281.6 |
